Parkinson’s Treatment Report

www.ParkinsonsTreatmentReport.com

News

Parkinson’s disease is not one, but two diseases

https://www.sciencedaily.com/releases/2020/09/200922092156.htm

Parkinson’s disease is not one, but two diseases
Date:
September 22, 2020
Source:
Aarhus University
Summary:
Researchers around the world have been puzzled by the different symptoms and varied disease pathways of Parkinson’s patients. A major study has now identified that there are actually two types of the disease.

Solving a Parkinson’s disease puzzle through protein design: breakthrough will open up a new dimension in drug discovery for Parkinson’s disease

https://www.sciencedaily.com/releases/2020/06/200611094114.htm

Solving a Parkinson’s disease puzzle through protein design
Date:
June 11, 2020
Source:
Ecole Polytechnique Fédérale de Lausanne
Summary:
Scientists have developed a computational protein design approach, and used it to obtain the first ever high-resolution structure of an activated dopamine receptor in its natural cell membrane environment. The breakthrough will open up a new dimension in drug discovery for Parkinson’s disease and perhaps other disorders.

Molecule BT13 offers hope for halting Parkinson’s: has potential to boost dopamine levels and protect dopamine-producing brain cells from dying

https://www.sciencedaily.com/releases/2020/02/200214183216.htm

Molecule offers hope for halting Parkinson’s

Date:
February 14, 2020

Source:
Parkinson’s UK

Summary:
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.

A promising molecule has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.

Researchers from the University of Helsinki found that molecule BT13 has the potential to both boost levels of dopamine, the chemical that is lost in Parkinson’s, as well as protect the dopamine-producing brain cells from dying.

San Diego biotech uses advanced stem cell techniques in hopes of rolling back the clock on Parkinson’s symptoms

https://www.sandiegouniontribune.com/business/biotech/story/2019-12-13/aspen-neuroscience-raises-funds-to-pursue-personalized-cell-therapy-for-parkinsons-disease

Aspen Neuroscience gets funding to pursue personalized cell therapy for Parkinson’s disease

San Diego biotech uses advanced stem cell techniques in hopes of rolling back the clock on Parkinson’s symptoms
By MIKE FREEMAN
DEC. 13, 2019 6 AM

Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype?

https://www.eurekalert.org/pub_releases/2019-11/ip-ftt111519.php

Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype?

Scientists review the evidence for using fecal transplantation and pre- and probiotics in patients with Parkinson’s disease in the Journal of Parkinson’s Disease

Scientists find potential diagnostic tool, treatment for Parkinson’s disease

http://med.stanford.edu/news/all-news/2019/09/scientists-find-potential-diagnostic-tool-treatment.html

Scientists find potential diagnostic tool, treatment for Parkinson’s disease
In human cell cultures, countering a defect that appears to be nearly universal among patients with Parkinson’s disease prevents death in the cells whose loss causes the disease.

Prostate drug (terazosin) may slow Parkinson’s disease

https://www.bbc.com/news/health-49713407

Prostate drug may slow Parkinson’s disease

A drug used to treat enlarged prostates may be a powerful medicine against Parkinson’s disease, according to an international team of scientists.

#terazosin

Biogen begins recruiting patients for phase 1 clinical trial of BIIB094 for Parkinson’s disease

According to ClinicalTrials.gov, the BIIB094 study record was updated on August 26, 2019. That is when the recruitment status of the study was changed from Not Yet Recruiting to Recruiting.

The estimated enrollment (number of patients able to participate in this phase of the trial) is 62 and the study is scheduled to start on September 21, 2019. (Which suggests that anyone who wants to participate in this trial should probably hurry – while there are still spots remaining.)

Here is some more information from the official BIIB094 clinical trial page and also a link to the study page where you can find all the important details, contact information, and so on.

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with Parkinson’s Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094. The study is open for PD patients with verified presence or absence of mutations in the leucine-rich repeated kinase 2 (LRRK2) gene, but also for patients without any verified PD-related genetic mutation.

STUDY LINK: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson’s Disease

LOCATIONS (Where is the study taking place?)

The study is currently recruiting in 3 locations: Michigan, Tennessee, and Washington.

COMMENT: For more Parkinson’s disease treatment-related updates and news via email, subscribe. For questions or comments to help improve this site, email michael@urgentresearch.com and say hello.

Nobiletin, a citrus flavonoid, has the potential to become a novel drug for the treatment of Parkinson’s, according to researchers in Japan

The new study was published online in the International Journal of Molecular Science on July 10, 2019.

You can read the full paper here: Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer’s Disease and Parkinson’s Disease.

Here is the abstract:

Alzheimer’s disease (AD), which is characterized by the presence of amyloid-β (Aβ) plaques and neurofibrillary tangles, accompanied by neurodegeneration, is the most common form of age-related neurodegenerative disease. Parkinson’s disease (PD) is the second most common neurodegenerative disease after AD, and is characterized by early prominent loss of dopaminergic neurons in the substantia nigra pars compacta. As currently available treatments are not able to significantly alter the progression of these diseases, successful therapeutic and preventive interventions are strongly needed. In the course of our survey of substances from natural resources having anti-dementia and neuroprotective activity, we found nobiletin, a polymethoxylated flavone from the peel of Citrus depressa. Nobiletin improved cognitive deficits and the pathological features of AD, such as Aβ pathology, hyperphosphorylation of tau, and oxidative stress, in animal models of AD. In addition, nobiletin improved motor and cognitive deficits in PD animal models. These observations suggest that nobiletin has the potential to become a novel drug for the treatment and prevention of neurodegenerative diseases such as AD and PD.

Int J Mol Sci. 2019 Jul 10;20(14):
Authors: Nakajima A, Ohizumi Y

For more information and science related to the citrus in question, Citrus depressa – “a small, green citrus fruit rich in flavonoids and native to Taiwan and Okinawa, Japan” – here are some more links:

https://en.wikipedia.org/wiki/Citrus_depressa

https://idtools.org/id/citrus/citrusid/factsheet.php?name=Shekwasha

https://www.science.gov/topicpages/s/shiikuwasha+citrus+depressa.html

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson’s Disease

https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-acceptance-of-new-drug-application-for-opicapone-as-an-adjunctive-treatment-for-patients-with-parkinsons-disease-300882953.html

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson’s Disease

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation, Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019

https://www.globenewswire.com/news-release/2019/07/08/1879407/0/en/Prevail-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-PR001-for-the-Treatment-of-Parkinson-s-Disease-Patients-with-a-GBA1-Mutation.html

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation

Company Plans to Initiate Phase 1/2 Clinical Trial in the Second Half of 2019

Emerald Health Pharmaceuticals Demonstrates Neuroprotective Activity of Novel Cannabigerol Derivatives in Huntington’s and Parkinson’s Disease Models

https://www.globenewswire.com/news-release/2019/07/02/1877328/0/en/Emerald-Health-Pharmaceuticals-Demonstrates-Neuroprotective-Activity-of-Novel-Cannabigerol-Derivatives-in-Huntington-s-and-Parkinson-s-Disease-Models.html

Emerald Health Pharmaceuticals Demonstrates Neuroprotective Activity of Novel Cannabigerol Derivatives in Huntington’s and Parkinson’s Disease Models

Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University

https://www.globenewswire.com/news-release/2019/06/27/1875104/0/en/Seelos-Therapeutics-Announces-Acquisition-of-an-Exclusive-Worldwide-License-of-Gene-Therapy-Program-to-Address-Parkinson-s-Disease-from-Duke-University.html

Seelos Therapeutics Announces Acquisition of an Exclusive Worldwide License of Gene Therapy Program to Address Parkinson’s Disease from Duke University

Neurocrine Biosciences to Present Data on Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders

https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-world-congress-on-parkinsons-disease-and-related-disorders-300865804.html

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson’s Disease and Related Disorders

– INGREZZA Data from Long-Term Phase III Studies Support Sustained Clinical Benefit, Safety and Tolerability in Patients with Tardive Dyskinesia

– Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson’s Disease and Motor Fluctuations

Parkinson’s: New gene therapy shows promise for prevention

https://www.medicalnewstoday.com/articles/325407.php

Parkinson’s: New gene therapy shows promise for prevention
Published Today By Maria Cohut Fact checked by Isabel Godfrey
The hallmarks of Parkinson’s disease and some forms of dementia include Lewy bodies, toxic aggregates that form in the brain and disrupt neural circuits. Researchers from Osaka University in Japan are now testing a new preventive therapy in a preliminary mouse study.

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients

https://www.biospace.com/article/neurocrine-biosciences-presents-phase-iii-data-analysis-demonstrating-that-opicapone-added-to-levodopa-resulted-in-a-significant-and-sustained-increase-in-on-time-without-troublesome-dyskinesia-in-parkinson-s-disease-patients/

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients

Parkinson’s results beyond researchers’ wildest dreams

https://www.bbc.com/news/health-47803496

Parkinson’s results beyond researchers’ wildest dreams

A treatment that has restored the movement of patients with chronic Parkinson’s disease has been developed by Canadian researchers.

Small Trial Provides New Hope Against Parkinson’s Disease

https://www.usnews.com/news/health-news/articles/2019-03-01/small-trial-provides-new-hope-against-parkinsons-disease

https://consumer.healthday.com/cognitive-health-information-26/parkinson-s-news-526/small-trial-provides-new-hope-against-parkinson-s-disease-743154.html